What is DynamiCare? DynamiCare is a smartphone-delivered digital care program that combines contingency management (financial incentives), remote substance testing, recovery coaching, and evidence-based behavioural content to support people with substance use disorders and those seeking moderation. The platform enables remote breath and saliva testing (submitted via selfie video), GPS-verified attendance tracking, telehealth coaching, and a […]
Feature Categories
What is DynamiCare?
DynamiCare is a smartphone-delivered digital care program that combines contingency management (financial incentives), remote substance testing, recovery coaching, and evidence-based behavioural content to support people with substance use disorders and those seeking moderation. The platform enables remote breath and saliva testing (submitted via selfie video), GPS-verified attendance tracking, telehealth coaching, and a smart debit card to deliver incentives while blocking risky spending.
DynamiCare’s program is designed for multi-month engagement (commonly up to 12 months) and has been implemented in payer and community settings to complement medication-assisted treatment and other modalities. It emphasises measurable behaviour change by automating CM workflows and providing coaches and family support tools.
Why Leading Healthcare Teams Trust DynamiCare
- The FDA granted Breakthrough Device Designation for DCH-002, a prescription digital therapeutic for alcohol use disorder, recognising it as a potential medical breakthrough. The FDA also designated DCH-001, a prescription treatment for tobacco smoking cessation during pregnancy, as a Breakthrough Device.
- The platform automates contingency management, an evidence-based methodology demonstrated to be effective in over 100 randomised controlled trials. A Johns Hopkins University study found that patients receiving DynamiCare were eight times more likely to remain in treatment past 90 days and had verified abstinence rates twice as high as controls.
- The HHS Office of Inspector General issued a favourable advisory opinion concluding that DynamiCare's contingency management program, which allows up to $599 in monetary incentives per patient, will not incur sanctions under the federal Anti-Kickback Statute or Beneficiary Inducement Prohibition. DynamiCare is the only company to receive this favourable HHS-OIG advisory opinion for contingency management.
- DynamiCare received a $1.6 million grant from NIAAA to conduct a multi-site, 12-month randomised controlled trial of DCH-002. The company has received three NIH grants and won the $1 million Ohio Opioid Technology Challenge.
- DynamiCare maintains HIPAA compliance with a published Notice of HIPAA Privacy Practices and applies tight controls for research studies conducted under Institutional Review Board oversight.
- DynamiCare's partners include Horizon Blue Cross Blue Shield of New Jersey, Vermont Medicaid, ComPsych, Spring Health, Johns Hopkins University School of Medicine, and the University of Vermont.
- DynamiCare Health has made no investments or acquisitions. The company remains independently operated, having raised over $6 million in equity funding and $5 million in grants and prizes.
Top 3 Pain Points DynamiCare Fixes in Healthcare
| Problem | How DynamiCare Solves It |
|---|---|
| 1. Low engagement and relapse rates in substance use disorder treatment | Uses digital contingency management with real-time rewards, coaching, and progress tracking to boost motivation, adherence, and recovery outcomes. |
| 2. Limited access to consistent recovery support and monitoring | Provides remote breath and saliva testing, GPS-verified check-ins, and telehealth coaching via mobile app — enabling continuous, accessible support from anywhere. |
| 3. Difficulty measuring outcomes and accountability at scale | Delivers verifiable data on testing, attendance, and engagement through an integrated platform, giving payers and providers measurable, data-driven insights. |
Feature Category Summary: DynamiCare
| Feature Category | Summary | Association (YES, NO, NA) |
|---|---|---|
| Regulatory-Ready | DynamiCare’s prescription-only digital therapeutics DCH-001 and DCH-002 for smoking cessation in pregnancy and alcohol use disorder have received FDA Breakthrough Device Designation, with the company engaging FDA through the Breakthrough Devices Program toward marketing authorization, indicating an active regulatory pathway but not yet full FDA clearance; there is no public mention of EMA or formal GxP validation frameworks beyond standard medical device processes. | YES |
| Clinical Trial Support | The platform is the subject of multiple randomized and feasibility trials as an intervention (e.g., a two-arm randomized trial of the DynamiCare app-based contingency management intervention in methadone treatment and published feasibility studies for alcohol use disorder), but there is no evidence that DynamiCare is used as a generic tool for protocol design, broader patient recruitment workflows, or sponsor-side trial operations. | NA |
| Supply Chain & Quality | No public documentation indicates features for manufacturing quality management, pharmaceutical or device supply chain integrity, or counterfeit detection; the platform is described as a digital therapeutic and recovery platform without references to production QA or logistics modules. | NO |
| Efficiency & Cost-Saving | DynamiCare’s contingency management engine automates remote substance testing, financial incentives, and monitoring (including real-time app displays of tests, rewards, and balances), and published studies describe staff review and incentives as part of the intervention, but there is no quantified claim of investigator or clinician time savings or formal health-economic efficiency metrics in the core marketing materials. | NA |
| Scalable / Enterprise-Grade | The company positions its Digital Recovery Platform as a scalable solution for addiction treatment and notes collaborations with health plans and systems that have conducted rigorous third-party risk assessments, but there is no explicit claim of deployment in large pharma/biotech enterprises or formal SaaS multi-tenant controls tailored to life-science R&D at scale. | NA |
| HIPAA Compliant | DynamiCare states that its app uses a HIPAA-compliant platform with encryption in transit and at rest and that the organization has a HIPAA Seal of Compliance from Compliancy Group, also referencing its Notice of HIPAA Privacy Practices and adherence to HIPAA regulations in the privacy policy. | YES |
| Clinically Validated | Peer-reviewed feasibility and randomized studies of the DynamiCare app for substance use disorders demonstrate engagement and impact on treatment participation, and DCH-001/DCH-002 are being evaluated in NIAAA-funded and other multi-site randomized controlled trials as prescription digital therapeutics, providing explicit clinical validation activities for the intended addiction treatment use cases. | YES |
| EHR Integration | Public materials, trial descriptions, and product pages do not mention integration with EHR systems (e.g., HL7, FHIR, SMART on FHIR) or direct embedding into clinical record workflows; the focus is on app-based testing, incentives, and telehealth recovery support rather than record-system interoperability. | NO |
| Explainable AI | The solution is framed around behavioral science–based contingency management, remote testing, and incentives, and available documentation does not describe AI/ML models providing clinical insights or any formal explainability methods such as feature attribution, model transparency dashboards, or clinician-facing rationales. | NO |
| Real-Time Analytics | The app displays results in real time for each test and maintains an updated record of testing compliance, rewards, and balances visible to the user and staff, but there is no explicit description of broader real-time analytics dashboards or streaming analytics modules beyond this real-time feedback loop for testing and incentives. | YES |
| Bias Detection | No public documentation references algorithmic bias assessment, demographic subgroup performance analysis, or tooling to identify or document bias in recommendation or incentive algorithms for different clinical sub-cohorts. | NO |
| Ethical Safeguards | DynamiCare emphasizes evidence-based contingency management, informed consent and HIPAA privacy practices, and compliance with health privacy regulations, but there is no detailed description of explicit AI governance controls such as configurable use-case restrictions, formal human-in-the-loop override policies, or algorithm governance boards beyond standard clinical oversight in trials and care delivery. | NA |
Risks & Limitations: DynamiCare
-
Predictive performance and program effectiveness depend on participant engagement and data quality; inconsistent remote submissions or device failures can reduce measurable impact.
-
Outputs are decision-support and behavioural incentives; clinical oversight and human coaching remain required for complex cases.
-
Integration with proprietary EHRs, payer claims platforms, or employer systems may require significant IT and contractual effort.
-
Regulatory, privacy, or compliance review may be required when using outputs for clinical decision-making, criminal justice monitoring, or payer reimbursement models.
-
Financial-incentive programs require careful design to avoid unintended negative consequences (gaming, dependency on incentives) and to ensure ethical administration.
Share This AI Tool
Get a neutral, no obligation view of whether this AI tool fits your portfolio
